Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease

Behavioural Brain Research

Volumn 151, Issue 1-2, 2004, Pages 191-199

  Srinivasan, J ^a   Schmidt, Werner J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

D Amphetamine; Dopamine; L DOPA; Locus coeruleus; Noradrenaline; Parkinson's disease

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; AMPHETAMINE; LEVODOPA; NORADRENALIN; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BEHAVIOR; BRAIN INJURY; CATALEPSY; DENERVATION; DOPAMINERGIC ACTIVITY; DRUG POTENTIATION; HYPERACTIVITY; INTERMETHOD COMPARISON; MALE; NERVE ENDING; NEUROCHEMISTRY; NONHUMAN; NORADRENERGIC NERVE; OPEN FIELD TEST; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENERGIC AGENTS; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; BENZYLAMINES; BRAIN CHEMISTRY; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; HOMOVANILLIC ACID; LEVODOPA; LOCUS COERULEUS; MALE; MOTOR ACTIVITY; NOREPINEPHRINE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STATISTICS, NONPARAMETRIC; TYROSINE;

EID: 16544386496     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2003.08.016     Document Type: Article

References (61)

1. Agid Y., Ahlskog E., Albanese A., Calne D., Chase T., De Yebenes J.et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov. Disord. 14:1999;911-913.
2. Antelman SN, Caggiula AR. Norepinephrine-dopamine interactions: one step beyond. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson's disease. Boca Raton: CRC Press; 1994. p. 127-38.
3. Alvord Jr EC, Forno LS. Pathology. In: Koller WC, editor. Handbook of Parkinson's disease. New York: Marcel Dekker; 1992. p. 258-9.
4. Arai N., Isaji M., Kojima M., Mizuta E., Kuno S. Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys. J. Neural. Transm. 103:1996;1307-1316.
5. Bing G., Zhang Y., Watanabe Y., McEwen B.S., Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668:1994;261-265.
6. Blandini F., Nappi G., Greenamyre J.T. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann. Neurol. 49:2001;525-529.
7. Chopin P., Colpaert F.C., Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hxdroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288:1999;798-804.
8. Colpaert F.C., Degryse A.D., Van Craenendonck H.V. Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs. Brain Res. Bull. 26:1991;627-631.
9. Constantinidis J., Bartholini G., Tissot R., Pletscher A. Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain. Experientia. 24:1968;130-131.
10. Dausse J.P., Le Quan-Bui K.H., Meyer P. Alpha 1- and alpha 2-adrenoceptors in rat cerebral cortex: effects of neonatal treatment with 6-hydroxydopamine. Eur. J. Pharmacol. 78:1982;15-20.
11. Devoto P., Flore G., Pani L., Gessa G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol. Psychiatry. 6:2001;657-664.
12. Edwards D.J., Rizk M. Conversion of 3,4-dihydroxyphenylalanine and deuterated 3,4-dihydroxyphenylalanine to alcoholic metabolites of catecholamines in rat brain. Journal of Neurochemistry. 36:1981;1641-1647.
13. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihn Verholten bei Erkrankungen des extrapyramidalen systems. Wien Klin Wochenschr. 38:1960;1236-1239.
14. Ferrucci M., Gesi M., Lenzi P., Soldani P., Ruffoli R., Pellegrini A.et al. Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls. Neurol. Sci. 23:2002;S75-S76.
15. Fornai F., Alessandri M.G., Torracca M.T., Bassi L., Corsini G.U. Effects of noradrenergic lesions on MPTP/MPP + kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther. 283:1997;100-107.
16. Fornai F., Bassi L., Torracca M.T., Scalori V., Corsini G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283:1995;99-102.
17. Fornai F., Giorgi F.S., Alessandri M.G., Giusiani M., Corsini G. Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-Bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and strital dopamine losses. J. Neurochem. 72:1999;777-784.
18. Fornai F., Torracca M.T., Bassi L., D'Errigo D.A., Scalori V., Corsini G.U. Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res. 735:1996;349-353.
19. Fox S.H., Henry B., Hill M.P., Peggs D., Crossman A.R., Brotchie J.M. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov. Disord. 16:2001;642-650.
20. Gerlach J. Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism. Psychopharmacology (Berl). 51:1997;259-263.
21. Gesi M., Soldani P., Giorgi F.S., Santinami A., Bonaccorsi I., Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 24:2000;655-668.
22. Giorgi F.S., Ferrucci M., Lazzeri G., Pizzanelli C., Lenzi P., Alessandri M.G.et al. A damage to locus coeruleus neurons converts sporadic seizures into self- sustaining limbic status epilepticus. Eur. J. Neurosci. 17:2003;2593-2601.
23. Goetz C.G., Klawans H.L. Chronic agonist-induced hypersensitivity and on-off hyperkinesis. Ann. Neurol. 6:1979;277-278.
24. Grondin R., Hadj Tahar A., Doan V.D., Ladure P., Bedard P.J. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn. Schmiedebergs Arch Pharmacol. 361:2000;181-186.
25. Harro J., Merikula A., Lepiku M., Modiri A.R., Rinken A., Oreland L. Lesioning of locus coeruleus projections by DSP-4 neurotoxin treatment: effect on amphetamine-induced hyperlocomotion and dopamine D2 receptor binding in rats. Pharmacol. Toxicol. 86:2000;197-202.
26. Heffner T.G., Hartman J.A., Seiden L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13:1980;453-456.
27. Henry B., Fox S.H., Peggs D., Crossman A.R., Brotchie J.M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14:1999;744-753.
28. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey S.P., Johannessen J.N. Selective retention of MPP+ within the dopaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience. 40:1991;133-158.
29. Himori N., Tanaka Y., Kurasawa M., Mishima K., Akaike N. 3-O-Methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse. Pharmacology. 48:1994;226-233.
30. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
31. Hossain M.A., Weiner N. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. J. Pharmacol. Exp. Ther. 267:1993;1105-1111.
32. Ihalainen J.A., Tanila H. In vivo regulation of dopamine and noradrenaline release by α2A-adrenoceptors in the mouse prefrontal cortex. Eur. J. Neurosci. 15:2002;1789-1794.
33. Jenner P., Marsden C.D. Neuroleptic-induced tardive dyskinesia. Acta Psychiatr. Belg. 87:1987;566-598.
34. Jenner P., Marsden C.D. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology. 26:1987;931-940.
35. Korczyn A.D., Nisipeanu P. Newer therapies for Parkinson's disease. Neurol. Neurochir. Pol. 30(Suppl 2):1996;105-111.
36. Kuno S. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications. Eur. Neurol. 38(Suppl 1):1997;18-22.
37. Marien M., Briley M., Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236:1993;487-489.
38. Marien M, Lategan A, Colpaert FC. Noradrenergic control of striatal dopamine. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson's disease. Boca Raton: CRC Press; 1994. p. 127-38.
39. Martel J.C., Chopin P., Colpaert F., Marien M. Neuroprotective effects of the α2-adrenoceptor antagonists (+)-Efaroxan and (±)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Exp. Neurol. 154:1998;595-601.
40. Maruyama W., Naoi M., Narabayashi H. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. J. Neurol. Sci. 139:1996;141-148.
41. Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience. 41:1991;507-523.
42. Melamed E., Rosenthal J., Cohen O., Globus M., Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur. J. Pharmacol. 116:1985;179-181.
43. Mogilnicka E. Increase in beta- and alpha 1-adrenoceptor binding sites in the rat brain and in the alpha 1-adrenoceptor functional sensitivity after the DSP-4-induced noradrenergic denervation. Pharmacol. Biochem. Behav. 25:1986;743-746.
44. Nakazato T., Akiyama A. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. Brain Res. 15:2002;134-142.
45. 2- adrenoceptor antagonists on extracellular dopamine concentrations in the rat striatum. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson's disease. Boca Raton: CRC Press, 1994; p. 127-38.
46. Paden C., Wilson C.J., Groves P.M. Amphetamine-induced release of dopamine from the substantia nigra in vitro. Life Sci. 19:1976;1499-1506.
47. Pycock C., Dawbarn D., O'Shaughnessy C. Behavioural and biochemical changes following chronic administration of L-dopa to rats. Eur. J. Pharmacol. 79:1982;201-215.
48. Pycock C.J., Marsden C.D. Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease. J. Neurol. Sci. 31:1977;113-121.
49. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C.et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16:2001;708-713.
50. Romero J.A., Chalmers J.P., Cottman K., Lytle L.D., Wurtman R.J. Regional effects of L-dihydroxyphenylalanine (L-DOPA) on norepinephrine metabolism in rat brain. J. Pharmacol. Exp. Ther. 180:1971;277-285.
51. Schmidt W.J. Basal ganglia dopamine and glutamate in motor activation and plasticity. Neurol Psych Brain Res. 6:1998;155-160.
52. Schmidt W.J. Dopamine-glutamate interactions in the basal ganglia. Amino Acids. 14:1998;5-10.
53. Schmidt W.J., Bubser M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav. 32:1989;621-623.
54. Speciale S.G., Liang C.L., Sonsalla P.K., Edwards R.H., German D.C. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience. 84:1998;1177-1185.
55. Srinivasan J, Schmidt WJ. Potentiation of Parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci, In press.
56. Sutin J., Minneman K.P. Alpha 1- and beta-adrenergic receptors are co-regulated during both noradrenergic denervation and hyperinnervation. Neuroscience. 14:1985;973-980.
57. Tassin JP, Trovero F, Blanc G, Herve D, Glowinski J. Interactions between noradrenaline and dopamine neurotransmission in the rat prefrontal cortex and their consequences on dopaminergic subcortical function. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson's disease. Boca Raton, CRC Press; 1994. p. 127-38.
58. Tolwani R.J., Jakowec M.W., Petzinger G.M., Green S., Waggie K. Experimental models of Parkinson's disease: insights from many models. Lab. Anim. Sci. 49:1999;363-371.
59. Turjanski N., Lees A.J., Brooks D.J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. 49:1997;717-723.
60. Verhagen M.L., Del Dotto P., Blanchet P.J., van den Munckhof P., Chase T.N. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14:1997;75-82.
61. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 60:2003;337-341.